SEC Form 4 · accession 0000950142-16-004060
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Andrew N Schiff
10% Owner
Steve Elms
10% Owner
Dennis J Purcell
10% Owner
AISLING CAPITAL III LP
10% Owner
Aisling Capital Partners III LP
10% Owner
Aisling Capital Partners III LLC
10% Owner
Period of report
Jul 6, 2016
Accepted (ET)
Jul 6, 2016 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 6, 2016 | C | 508,565 | — | A | 508,565 | D | |
| Common StockF2 | Jul 6, 2016 | P | 400,000 | $12.50 | A | 908,565 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF2,F1 | — | Jul 6, 2016 | C | 1,907,122 | D | — | — | Common Stock | 508,565 | 0 | D |
Explanation of responses
- F1The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- F2The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms.